Electronic Fields to Enhance Pancreatic Cancer Chemotherapy
A clinical trial uses electric fields to help slow the growth of tumor cells, In a clinical trial for pancreatic cancer patients.
Finding a Safe Dose of a New Drug for Some Types of Solid Tumors
LMB-100 is a lab-created protein that targets mesothelin. It is being tested against pancreatic cancer and other solid tumors in a clinical trial.
Radiotherapy Implant plus Standard Chemotherapy
The OncoSil radiotherapy implant device is being tested on pancreatic cancer in a clinical trial that combines it with standard chemotherapy.
A New Combination Chemotherapy Before Surgery
A new clinical trial adds vitamin D to standard of care chemotherapy before surgery, to make pancreatic cancer tumors more removable.
Finding the Best Dose of Radiation and an Experimental Drug
A clinical trial looks for the best dose of an experimental drug to combat the mouth sores that are a side effect of radiation treatment.
Noninvasive Surgery and a New Drug to Stop Pancreatic Tumors
A clinical trial combines irreversible electroporation (IRE) and immunotherapy to see if the duo is effective against locally advanced pancreatic cancer.
Chemotherapy, Immunotherapy, and Radiation for Locally Advanced Pancreatic Cancer
A clinical trial is testing chemotherapy that enhances the action of two immunotherapy drugs and SBRT to stop locally advanced pancreatic cancer.
More Effective Focused Radiation Therapy and Chemotherapy for Locally Advanced Pancreatic Cancer
A clinical trial tests whether adding Zometa makes chemotherapy and stereotactic body radiation therapy (SBRT) more effective against pancreatic cancer.
Testing the Safety of a New Chemotherapy and Radiation Combination
A clinical trial tests the effectiveness of adding PEGPH20 to standard chemotherapy and radiation in patients with locally advanced pancreatic cancer.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
- 1
- 2
